Thrombocytosis
AI Schafer - New England Journal of Medicine, 2004 - Mass Medical Soc
Thrombocytosis is usually discovered incidentally, but the differential diagnosis is important.
In cases of reactive, or secondary, thrombocytosis, the underlying disease may require …
In cases of reactive, or secondary, thrombocytosis, the underlying disease may require …
Glucose-6-phosphate dehydrogenase deficiency: a historical perspective
E Beutler - Blood, The Journal of the American Society of …, 2008 - ashpublications.org
Glucose-6-phosphate dehydrogenase deficiency serves as a prototype of the many human
enzyme deficiencies that are now known. Since its discovery more than 50 years ago, the …
enzyme deficiencies that are now known. Since its discovery more than 50 years ago, the …
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Background Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are
clonal myeloproliferative disorders arising from a multipotent progenitor. The loss of …
clonal myeloproliferative disorders arising from a multipotent progenitor. The loss of …
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
JJ Kiladjian, B Cassinat, S Chevret… - Blood, The Journal …, 2008 - ashpublications.org
Abstract Interferon-α (IFN-α) is a nonleukemogenic treatment of polycythemia vera (PV) able
to induce cytogenetic remissions. Its use is limited by toxicity, leading to treatment …
to induce cytogenetic remissions. Its use is limited by toxicity, leading to treatment …
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
A Quintás-Cardama, O Abdel-Wahab… - Blood, The Journal …, 2013 - ashpublications.org
Pegylated interferon α-2a (PEG-IFN-α-2a) has previously been shown to induce
hematologic and molecular responses in patients with polycythemia vera (PV) or essential …
hematologic and molecular responses in patients with polycythemia vera (PV) or essential …
Expression of Jak2V617F causes a polycythemia vera–like disease with associated myelofibrosis in a murine bone marrow transplant model
G Wernig, T Mercher, R Okabe, RL Levine, BH Lee… - Blood, 2006 - ashpublications.org
An acquired somatic mutation, Jak2 V617F, was recently discovered in most patients with
polycythemia vera (PV), chronic idiopathic myelofibrosis (CIMF), and essential …
polycythemia vera (PV), chronic idiopathic myelofibrosis (CIMF), and essential …
Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
A Theocharides, M Boissinot, F Girodon… - Blood, The Journal …, 2007 - ashpublications.org
To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27
patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid …
patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid …
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
JJ Kiladjian, S Giraudier, B Cassinat - Leukemia, 2016 - nature.com
Interferon alpha (IFN-α) has been used for over 30 years to treat myeloproliferative
neoplasms (MPNs). IFN-α was shown to induce clinical, hematological, molecular and …
neoplasms (MPNs). IFN-α was shown to induce clinical, hematological, molecular and …
The renaissance of interferon therapy for the treatment of myeloid malignancies
JJ Kiladjian, RA Mesa… - Blood, The Journal of the …, 2011 - ashpublications.org
IFNα has been used to treat malignant and viral disorders for more than 25 years. Its efficacy
is likely the consequence of its broad range of biologic activities, including direct effects on …
is likely the consequence of its broad range of biologic activities, including direct effects on …
[PDF][PDF] Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
M Primignani, G Barosi, G Bergamaschi… - …, 2006 - Wiley Online Library
The diagnosis of an underlying chronic myeloproliferative disorder (CMPD) is often
problematic in patients with primary extrahepatic portal vein obstruction (EHPVO) or Budd …
problematic in patients with primary extrahepatic portal vein obstruction (EHPVO) or Budd …